VANDRIA SA

Vandria SA is a clinical-stage biotechnology company that develops first-in-class small molecule therapeutics designed to improve mitochondrial function and reduce chronic inflammation. By targeting processes such as mitophagy—the cellular mechanism for replacing damaged mitochondria—the company aims to address the underlying causes of various age-related and chronic diseases. Its proprietary research focuses on a novel metabolic target with strong genetic associations to neurodegenerative conditions, lung, liver, and muscle diseases. The company's lead clinical asset, VNA-318, is an orally available, brain-penetrant small molecule that has completed Phase 1 clinical studies, showing potential for cognitive improvement and disease-modifying effects in disorders such as Alzheimer’s and Parkinson’s disease.

Headquartered in Epalinges, Switzerland, and founded in 2021 as a spin-out from Amazentis SA, Vandria serves partners and investors seeking to address high-unmet medical needs in neurodegeneration and metabolic decline. Supported by venture funding from firms including ND Capital, Hevolution Foundation, and Dolby Family Ventures, the company utilizes its R&D platform to progress a pipeline of new chemical entities. These therapeutics are engineered to rejuvenate cells by restoring oxidative phosphorylation pathways, reducing protein aggregation, and protecting against cell death, providing a foundation for potential future clinical efficacy trials in diverse indications.